These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23547755)

  • 21. Emerging paradigms and recent progress in targeting ErbB in cancers.
    Stoup N; Liberelle M; Lebègue N; Van Seuningen I
    Trends Pharmacol Sci; 2024 Jun; 45(6):552-576. PubMed ID: 38797570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting EGFR in pancreatic cancer treatment.
    Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
    Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy.
    Cheng W; Zhou J; Tian X; Zhang X
    Curr Med Chem; 2016; 23(29):3343-3359. PubMed ID: 27160532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor targeting in cancer.
    Mendelsohn J; Baselga J
    Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
    Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
    Grünwald V; Hidalgo M
    J Natl Cancer Inst; 2003 Jun; 95(12):851-67. PubMed ID: 12813169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities.
    Zubair T; Bandyopadhyay D
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR).
    Liao QH; Gao QZ; Wei J; Chou KC
    Med Chem; 2011 Jan; 7(1):24-31. PubMed ID: 21235516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Some implications of receptor kinase signaling pathway for development of multitargeted kinase inhibitors.
    Mitrasinovic PM
    Curr Radiopharm; 2013 Mar; 6(1):48-55. PubMed ID: 23278847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
    Planken S; Behenna DC; Nair SK; Johnson TO; Nagata A; Almaden C; Bailey S; Ballard TE; Bernier L; Cheng H; Cho-Schultz S; Dalvie D; Deal JG; Dinh DM; Edwards MP; Ferre RA; Gajiwala KS; Hemkens M; Kania RS; Kath JC; Matthews J; Murray BW; Niessen S; Orr ST; Pairish M; Sach NW; Shen H; Shi M; Solowiej J; Tran K; Tseng E; Vicini P; Wang Y; Weinrich SL; Zhou R; Zientek M; Liu L; Luo Y; Xin S; Zhang C; Lafontaine J
    J Med Chem; 2017 Apr; 60(7):3002-3019. PubMed ID: 28287730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insight into the medicinal chemistry of EGFR and HER-2 inhibitors.
    Wang C; Gao H; Dong J; Wang F; Li P; Zhang J
    Curr Med Chem; 2014; 21(11):1336-50. PubMed ID: 24251571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
    Yewale C; Baradia D; Vhora I; Patil S; Misra A
    Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
    Reddy PS; Lokhande KB; Nagar S; Reddy VD; Murthy PS; Swamy KV
    Curr Comput Aided Drug Des; 2018; 14(3):246-252. PubMed ID: 29493460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives.
    do Amaral DN; Lategahn J; Fokoue HH; da Silva EMB; Sant'Anna CMR; Rauh D; Barreiro EJ; Laufer S; Lima LM
    Sci Rep; 2019 Jan; 9(1):14. PubMed ID: 30626888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
    Juchum M; Günther M; Laufer SA
    Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer.
    Bonanno L; Jirillo A; Favaretto A
    Curr Drug Targets; 2011 Jun; 12(6):922-33. PubMed ID: 21443472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting HER receptors in cancer.
    Ocaña A; Pandiella A
    Curr Pharm Des; 2013; 19(5):808-17. PubMed ID: 22973952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
    Engel J; Smith S; Lategahn J; Tumbrink HL; Goebel L; Becker C; Hennes E; Keul M; Unger A; Müller H; Baumann M; Schultz-Fademrecht C; Günther G; Hengstler JG; Rauh D
    J Med Chem; 2017 Sep; 60(18):7725-7744. PubMed ID: 28853575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.